CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
暂无分享,去创建一个
N. Bartlett | M. Wei | Sung-Soo Yoon | E. Purev | F. Morschhauser | Chi-Chung Li | L. Nastoupil | M. Bishton | A. Bottos | A. Knapp | P. Giri | C. Scholz | Haocheng Li